Trial Profile
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie; AbbVie Germany
- 25 Jan 2023 Planned End Date changed from 23 Sep 2024 to 23 Aug 2024.
- 25 Jan 2023 Planned primary completion date changed from 23 Sep 2024 to 23 Aug 2024.
- 01 Aug 2022 Planned primary completion date changed from 22 Jun 2024 to 23 Sep 2024.